2023
Mass spectrometry on cerebrospinal fluid uncovers association of novel glycolysis biomarkers with Alzheimer’s disease in a complex clinical cohort
de Geus M, Leslie S, Wang W, Lam T, Broekman M, Neefjes S, Nairn A, Carlyle B, Arnold S. Mass spectrometry on cerebrospinal fluid uncovers association of novel glycolysis biomarkers with Alzheimer’s disease in a complex clinical cohort. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.078466.Peer-Reviewed Original ResearchAlzheimer's diseaseMild cognitive impairmentHospital neurology serviceNon-AD diagnosesDiagnostic lumbar puncturePrognosis of ADCerebrospinal fluid biomarkersClinic cohortFurther mechanistic studiesNeurology serviceFDG-PETBrain metabolismFluid biomarkersLumbar puncturePatient cohortClinical indicationsDisease progressionATN biomarkersClinical cohortTreatment responseComplex cohortBackground DiagnosisCSF samplesTreatment efficacyLinear regression analysis
2018
P1‐274: A TARGETED MASS‐SPECTROMETRY METHOD FOR QUANTIFICATION OF CEREBROSPINAL FLUID BIOMARKERS OF ALZHEIMER'S DISEASE
Carlyle B, Leslie S, Trombetta B, Nobuhara C, van Dyck C, Nairn A, Arnold S. P1‐274: A TARGETED MASS‐SPECTROMETRY METHOD FOR QUANTIFICATION OF CEREBROSPINAL FLUID BIOMARKERS OF ALZHEIMER'S DISEASE. Alzheimer's & Dementia 2018, 14: p387-p387. DOI: 10.1016/j.jalz.2018.06.280.Peer-Reviewed Original ResearchCerebrospinal fluid biomarkersFluid biomarkers